RT Journal Article
SR Electronic
T1 CovidArray: a microarray-based assay with high sensitivity for the detection of SARS-CoV-2 in nasopharyngeal swabs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.21.21250281
DO 10.1101/2021.01.21.21250281
A1 Damin, Francesco
A1 Galbiati, Silvia
A1 Gagliardi, Stella
A1 Cereda, Cristina
A1 Dragoni, Francesca
A1 Fenizia, Claudio
A1 Savasi, Valeria
A1 Sola, Laura
A1 Chiari, Marcella
YR 2021
UL http://medrxiv.org/content/early/2021/01/26/2021.01.21.21250281.abstract
AB Background A new coronavirus (SARS-CoV-2) caused the current Covid-19 epidemic. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) is used as the gold standard for clinical detection of SARS-CoV-2. Under ideal conditions RT-qPCR Covid-19 assays have analytical sensitivity and specificity greater than 95%. However, when the sample panel is enlarged including asymptomatic individuals, the sensitivity decreases and false-negative are reported. Moreover, RT-qPCR requires up to 3-6 hours with most of the time involved in RNA extraction from swab samples.Methods We introduce CovidArray, a microarray-based assay, to detect SARS-CoV-2 markers N1 and N2 in the nasopharyngeal swabs. The method is based on solid phase hybridization of fluorescently labelled amplicons upon RNA extraction and reverse transcription. This approach combines the physical-optical properties of the silicon substrate with the surface chemistry used to coat the substrate to obtain a diagnostic tool of great sensitivity. Furthermore, we used an innovative approach, RNAGEM, to extract and purify viral RNA in less than 15 minutes. To validate the CovidArray results, we exploited the high sensitivity of the droplet digital PCR (ddPCR) technique.Result We correctly assigned 12 nasopharyngeal swabs, previously analyzed by RT-qPCR. Thanks to the CovidArray sensitivity that matches that of the ddPCR, we were able to identify a false-negative sample.Conclusions CovidArray is the first DNA microarray-based assay to detect viral genes in the swabs. Its high sensitivity and the innovative viral RNA extraction by RNAGEM allows to reduce both the amount of false negative results and the total analysis time to about 2 hours.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project has received funding from the Horizon 2020 research and innovation programme of the European Union under grant agreement No 766466.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by the local Medical Ethical and Institutional Review Board (Milan, area 1, #154082020). We obtained the informed consent from the patients, according to CARE guidelines and in compliance with the Declaration of Helsinki principles.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this study are available on request from the corresponding authorCovid-19CoronaVirus Disease 19SARS-CoV-2severe acute respiratory syndrome coronavirus 2PCRpolymerase chain reactionRT-qPCRreverse transcription-quantitative polymerase chain reactionqPCRquantitative polymerase chain reactionCopoly(DMA-NAS-MAPS)N,N-dimethylacrylamide (DMA), N,N-acryloyloxysuccinimide (NAS), and 3-(trimethoxysilyl) propyl methacrylate (MAPS) copolymerddPCRdroplet digital PCRLODlimit of detectionRPP30Ribonuclease P geneSSCsaline sodium citrateSDSsodium dodecyl sulfateUTMuniversal transport mediumPMTphotomultiplier tube